The randomised, placebo-controlled, double-blind trial is anticipated to conclude next year.
It will also characterise UPB-101 based on a prior Phase I single ascending dose trial completed by Astellas Pharma in healthy subjects.
According to data from the Phase I trial, UPB-101 showed to possess a promising profile on safety, pharmacokinetics and pharmacodynamics measures.
UPB-101 is created to hinder the thymic stromal lymphopoietin receptor (TLSPR) and thereby hinder inflammation caused by a cytokine called TSLP.
TSLP plays a key role in triggering an inflammatory response in asthma as well as various other allergic and inflammatory ailments.
UPB-101 was found to hinder production of cytokine from CD4+ T cells and ILC2, in pre-clinical studies.
It also fully inhibited skin allergic reactions in a non-human primate model, indicating that it could be effective against various inflammation types.
Upstream Bio Research and Development head and chief medical officer Aaron Deykin said: “Our goals with this study are to further explore the impact of UPB-101 on relevant pharmacodynamic measures and to inform the dose regimen selection for Phase II investigation.
“TSLP receptor blockade is a novel approach to inhibiting TSLP-induced activation of multiple downstream pathways in asthma and is anticipated to have broad utility across many inflammatory phenotypes of patients.
“It is an emerging class of biologics for patients with moderate to severe asthma who, despite treatment with standard inhaled medications, still experience ongoing exacerbations and debilitating, sometimes life-threatening symptoms.”